On Friday, Tempus AI hit a noteworthy performance benchmark, with its Relative Strength (RS) Rating jumping into the 90-plus percentile with an upgrade to 92, an increase from 89 the day before.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique rating tracks price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks typically have an 80 or better RS Rating as they begin their largest price moves.
The IBD 50 stock is not currently near a potential buy zone. See if the stock goes on to form a chart pattern that could launch a new move.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 90%.
Tempus AI holds the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
